LSCs are known to be resistant to TKIs through BCR::ABL1-independent mechanisms [20], and so can persist after successful TKI-induced remission, acting as a reservoir for CML relapse. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.